Anti-SLAMF7 / Signaling lymphocytic activation molecule family member 7, clone SLAMF7/13123

0.2 mg/ml in 1X PBS with 0.05% BSA, 0.05% sodium azide. SLAMF7/CS1 antibody recognizes Signaling Lymphocytic Activation Molecule Family Member 7, a type I transmembrane glycoprotein encoded by the SLAMF7 gene and commonly referred to as CD319 and CRACC. CS1 is a member of the SLAM family within the immunoglobulin superfamily and is primarily expressed on natural killer cells, subsets of activated T lymphocytes, mature dendritic cells, and plasma cells. The protein is localized to the plasma membrane, where it mediates homotypic interactions and immune cell signaling through immunoreceptor tyrosine-based switch motifs in its cytoplasmic domain. These motifs recruit adaptor proteins such as EAT-2, enabling downstream activation of cytotoxic and adhesion pathways.Functionally, CS1 plays a key role in regulating innate and adaptive immune responses. Engagement of SLAMF7 enhances natural killer cell cytotoxicity and cytokine production, contributing to immune surveillance and tumor cell elimination. In plasma cells, CS1 supports cell adhesion and survival signaling, which has important implications in plasma cell neoplasms. High and consistent expression of SLAMF7 in multiple myeloma has made CS1 antibody an important research and diagnostic tool in hematopathology and immuno-oncology. Targeting CS1 has demonstrated clinical relevance in antibody-based therapeutic strategies designed to induce antibody-dependent cellular cytotoxicity against malignant plasma cells.The SLAMF7 gene is located on chromosome 1q23 within a cluster of SLAM family genes involved in immune regulation. Expression is largely restricted to hematopoietic lineages, with minimal detection in most non-hematopoietic tissues. In formalin-fixed tissues, CS1 expression is typically observed as membranous staining in plasma cells and natural killer cell populations, consistent with its surface receptor localization. This restricted pattern supports its utility in distinguishing plasma cell neoplasms and evaluating immune cell subsets within lymphoid tissues.This CS1 antibody (clone SLAMF7/13123) targets SLAMF7 in research applications. By enabling detection of CS1 expression, this antibody supports studies of immune cell activation, tumor microenvironment characterization, and plasma cell biology in normal and malignant tissues. By enabling reliable detection of CS1, this antibody supports studies of immune cell activation, tumor microenvironment characterization, and plasma cell biology in normal and malignant tissues.